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Abstract  33 
Approximately half of high-risk neuroblastoma (NB) is characterized by MYCN-amplification. N-Myc 34 
promotes tumor progression by inducing cell growth and inhibiting differentiation. MYCN has also been 35 
shown to play an active role in mitochondrial metabolism, but this relationship is not well understood. 36 
While N-myc is a known driver of the disease, it remains a target for which no therapeutic drug exists. Here, 37 
we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified (MNA) or 38 
MYCN-expressing NB, and investigated the mechanism of its anti-tumor activity. MYCN mRNA and cell 39 
viability were reduced in a broad set of NB cell lines following BGA002 treatment. Furthermore, BGA002 40 
decreased N-myc protein levels and apoptosis in MNA-NB. Analysis of gene expression data from 41 
neuroblastoma patients revealed that MYCN was associated with increased reactive oxygen species (ROS), 42 
downregulated mitophagy and poor prognosis. Inhibition of MYCN caused profound mitochondrial damage 43 
in MNA-NB cells through downregulation of the mitochondrial molecular chaperone TRAP1, which 44 
subsequently increased ROS. Correspondigly, inhibition of MYCN reactivated mitophagy. Systemic 45 
administration of BGA002 downregulated N-myc and TRAP1 with a concomitant decrease in MNA-NB 46 
xenograft tumor weight. In conclusion, this study highlights the role of N-myc in blocking mitophagy in NB 47 
and in conferring protection to ROS in mitochondria through upregulation of TRAP1. BGA002 is a potently 48 
improved MYCN-specific antigene oligonucleotide that reverts N-myc dysregulated mitochondrial 49 
pathways, leading to loss of the protective effect of N-myc against mitochondrial ROS. 50 
 51 
Significance: 52 
A second generation antigene peptide oligonucleotide targeting MYCN induces mitochondrial damage and 53 
inhibits growth of MYCN-amplified neuroblastoma cells. 54 
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Neuroblastoma (NB) is the deadliest pediatric tumor. While patients with a low or intermediate risk have a 58 
favorable outcome, the high-risk group has a survival rate below 50% (1). The latter group often presents  59 
with MYCN amplification (50% of the high risk group) (2). N-Myc is a well-known driver of the disease (3) 60 
and is strongly associated with poor survival prognosis (4,5). N-Myc promotes cell growth, inhibits cell 61 
differentiation while maintaining a stem-like phenotype; its  levels correlate with metastasis and the 62 
induction of angiogenesis (6,7). Furthermore, MYCN over-expression affects metabolism to support the 63 
higher energy demand of the tumor cells (8–10). Beyond increasing glycolysis and glutaminolysis, N-Myc is 64 
involved in mitochondrial functional alteration, however, the mechanism of this effect  is not fully 65 
understood (11). 66 
Interestingly, MYCN is expressed during embryogenesis and is virtually absent during adulthood (12). All 67 
these factors make N-Myc a promising target for neuroblastoma therapy. However, in order for an inhibitor 68 
to be effective, it should either interfere with the N-Myc/MAX heterodimers, or with N-Myc interaction 69 
with DNA, without inhibiting the highly homologous myc. These requirements have led to N-Myc being 70 
currently considered an unlikely target for therapeutic intervention (13).  71 
Although indirect therapeutic approaches in combating neuroblastoma by inhibiting N-Myc have been 72 
proposed, considering the broad role of MYCN in neuroblastoma and the lack of a complete understanding 73 
of its mechanism, the challenge still remains. Given the difficulties encountered in developing a small 74 
molecule inhibitor, other approaches including the use of oligonucleotides, have been tested to inhibit the 75 
MYC family (14,15). Differing from the use of antisense oligonucleotides, which inhibit mRNA translation, 76 
the antigene approach involves binding to chromosomal DNA, resulting in the inhibition of transcription.  77 
By persistently blocking transcription, the antigene oligonucleotides showed higher efficacy compared to 78 
antisense oligonucleotides (14–17). Furthermore, PNAs demonstrated potent and specific antigene activity 79 
(14–17) and higher therapeutic potential due to their resistance to nuclease degradation (18). 80 
In the present work we show for the first time that BGA002, a new and highly improved antigene PNA 81 
oligonucleotide, can specifically target a unique sequence on the MYCN gene. We also demonstrate a new 82 
mechanism for the inhibition of MYCN, and ultimately confirm the efficacy of BGA002 in vivo. 83 
 84 
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Materials and Methods 86 
 87 
Cell lines. All the cell lines used in this study were obtained during the 2018. Cell lines were obtained from 88 
DSMZ (KELLY, LAN5, CHP-134, SiMa, MHH-NB11, NGP, LS, NMB, LAN-1, LAN-6, LAN-2, NBL-S), ECACC 89 
(SK−N−DZ, SK-N-F1, NB69), ATCC (HEK293) and kindly gifted by Gaslini Institute, Genova (GI-LI-N, SMS-90 
KAN), by Professor Paolucci G. (SJ-N-KP), Professor Della Valle G (IMR32, SK-N-BE(2)-C, TET-21N) and by 91 
professor Spampinato SM (SH-SY5Y). All cell lines are stored in liquid nitrogen and kept in culture for a 92 
maximum of 30 days and less than 7 passages from the time they are obtained. The average number of 93 
passages for each cell line used in this study is 3. Cell line authentication was not conducted. Cell lines were 94 
verified to be negative for the presence of Mycoplasma every 3 months by a PCR-based method with the 95 
kit LookOut Mycoplasma PCR Detection Kit (Sigma Aldrich) using the manufacturer’s instructions. The list of 96 
cell lines used in this study with additional details is available as part of the supplementary materials 97 
(Supplementary Table 1). 98 
 99 
Cell line treatment.  BGA001 and BGA002 were produced by Biogenera. PNA-peptide was either available, 100 
stored at -20°C, and ready for use, or freshly produced by the Chemistry department and delivered to the 101 
Biology department after purification and dilution. PNA  was designed and prepared according to 102 
previously published studies (16,17). Cell lines were expanded in RPMI 1640, with 10% fetal bovine serum 103 
(FBS). Adherent cells were detached with PBS-EDTA, collected, washed, and centrifuged. Cells were 104 
counted and resuspended in OPTIMEM.  For PNA-peptide treatment (BGA001 and BGA002), 50000 cells 105 
were plated in a 24-well flat-bottom plate for RNA extraction, 5000 cells were plated in a 96-well flat-106 
bottom plate for cell viability assays. Cell lines were treated with increasing concentrations (range: 0.08 µM 107 
to a maximum of 20 µM) of PNA-peptide.  Small interfering RNA (siRNA) for MYCN (sense: 108 
UGAUGAAGAGGAAGAUGAAtt, antisense: UUCAUCUUCCUCUUCAUCAtt), TRAP1 (S179, Thermo Fisher 109 
Scientific) were mixed with Lipofectamine (Invitrogen) and then diluted in OPTIMEM. Fifty thousand cells 110 
were plated in a 24 well plate   and incubated with siRNA (100 nM MYCN siRNA, 50 nM TRAP1 siRNA). After 111 
6 hours of treatment, 4 % FBS was added to the cells.   112 
 113 
Quantitive real-time PCR. After 12 hours, the cell lines were detached with PBS-EDTA, centrifuged, and 114 
transferred to a 1.5 mL eppendorf tube. The pellet was lysed and stored at -20 °C. RNA was extracted using 115 
the RNAspin Mini RNA isolation Kit (GE Healthcare). Prior to use, each sample of RNA was quantified with 116 
the Nanodrop spectrophotometer (Thermo Fisher Scientific). One hundred ng of RNA was resuspended for 117 
each sample. Retrotranscription and real-time PCR was performed as previously described (17). The list of 118 
primers in this study is listed in Supplementary Table 2. Crossing points (Cp) from each analyte were 119 
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calculated using the second derivative maximum method, and the expression level was quantified by 120 
comparison to the BIRC4 gene. 121 
 122 
Cell viability assay. Four technical replicates were prepared for each experiment. After 72 hours of 123 
treatment, the cells were treated according to the CellTiter-Glo Luminescent Cell Viability Assay protocol 124 
(Promega). Luminescence was recorded with the Infinite F200 instrument (Tecan). The percentage of the 125 
effect was calculated based on mean luminescence of the control.  126 
 127 
Western blot. Cell were lysed 24 hours post treatment in sample lysing buffer (RIPA buffer (150 mM NaCl, 128 
1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) with Halt protease 129 
inhibitor cocktail (Thermo Fisher Scientific). For N-Myc staining, the pellet was resuspended in sample 130 
lysing solution on ice (about 50 µL for 5x10 5 cells), and homogenized with a probe sonicator on ice.  For 131 
OPTN, TRAP1, and, cytochrome c staining, mitochondria were isolated from cultured cells as previously 132 
described (19). Total protein extract was quantified using the BCA method with NanoDrop ND-1000 133 
spectrophotometer against a standard curve of BSA in sample lysing solution. Ten to thirty µg of protein 134 
was mixed with Bolt® Sample Reducing Agent (10X), and Bolt® LDS Sample Buffer (4X) (both from Thermo 135 
Fisher Scientific). The samples were then denatured and loaded with SeeBlue® Plus2 Pre-stained Protein 136 
Standard and SuperSignal® Enhanced Molecular Weight Protein Ladder onto a Polyacrylamide Bolt® Bis-Tris 137 
Plus Gel and run with Bolt® MES SDS Running Buffer (20X). The gel transfer was conducted with the iBlot™ 138 
Gel Transfer System. Five percent dry milk in PBS-Tween (1X PBS, 0.1% Tween-20) was used as the blocking 139 
solution. The membrane was incubated with the following antibodies: N-Myc (SCsc-53993, Santa Cruz), B-140 
Tubulin (SC-9104, Santa Cruz), OPTN (sc-166576C2, Santa Cruz), TRAP1 (sc-13557TR1, Santa Cruz), and 141 
Cytochrome C (sc-13156A8, Santa Cruz) diluted in 3.5% BSA, PBS-0.1% Tween-20. The secondary antibody 142 
used was anti-mouse antibody (SCsc-2031 HRP, Santa Cruz). Super Signal® West Pico was used as the HRP 143 
substrate. 144 
 145 
Apoptosis analysis. Kelly cell lines were treated as described above. The Tet21N cells were cultured with or 146 
without tetracycline for at least 72 hours and were then detached, washed, and stained with annexin V / PI 147 
(ROCHE) according to the manufacturer’s instructions.  The cell samples were analyzed by the CytoFLEX 148 
flow cytometer (Beckman Coulter). The data were analyzed with FlowJo software (Tree Star).  149 
 150 
Mitochondrial net analysis. Kelly (60.000 cells) were seeded on 12x12mm circular glass in a 24-well plate 151 
for 24 hours in Optimem medium, treated with 5 μM BGA002 or 50 nM TRAP1 siRNA with the addition of 152 
4% FBS 6 hours post treatment. At the end of the treatment, MitoTracker® Deep RedFM (M22426; Thermo 153 
Fisher Scientific) was added according to the manufacturer’s instructions. Cells were fixed with 4% PFA and 154 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 6 
were mounted on a glass slide with SlowFade ™ Diamond Antifade Mountant (S36967; Thermo Fisher 155 
Scientific). Images were acquired with a confocal microscope (Leica TCS LS).  ImageJ was used to capture 156 
the images. Briefly, the signal was reduced with a subtraction command with a value of 25 and the images 157 
were convolved with a Gaussian blur (σ =1) 158 
 159 
Transmission electron microscopy. Kelly cells were seeded onto a 24x24 mm square glass support in a 6-160 
well plate overnight. PNA oligo treatment was performed as described above. Tet21N cells, cultured for at 161 
least 72 hours with or without  tetracycline, were seeded as described above, and treated overnight with 162 
60 μM chloroquine (vesicular blocking) (20). After 24 hours, fixative solution (2.5% glutaraldehyde in 163 
cacodylate buffer 0.1M pH 7.4) was added for 2 hours. The samples were then stored in cacodylate buffer 164 
at 4°C. Cells were then post fixed with a solution of 1% osmium tetroxide in 0.1 M cacodylate buffer and 165 
embedded in epoxy resins after a graded-acetone serial dehydration step. Ultrathin slices of 100 nm were 166 
stained by uranyl acetate solution and lead citrate, and then analyzed by a transmission electron 167 
microscope, CM10 Philips (FEI Company) at an accelerating voltage of 80 kV. Images were recorded with a 168 
Megaview III digital camera (FEI Company).  169 
 170 
Bioinformatic analysis. Neuroblastoma arrays were downloaded (E-MTAB-1781) and normalized. Briefly, 171 
mitochondrial involved genes were selected from GO and the literature and used to train a self-organizing 172 
map and to cluster patient gene expression profiles. Survival and differential expression gene analyses were 173 
applied on the two found clusters. A self-organizing map and random forest model were used to perform 174 
feature selection to build a score. ClueGO application was used to find pathway enrichment networks 175 
differentially present in the two clusters. The genes in the ROS and Mitophagy pathway lists were obtained 176 
from the ClueGO analysis. A detailed description was presented for the bioinformatic data in the extended 177 
materials and methods (supplementary files). 178 
 179 
ROS measurement. Kelly and Tet21N cell lines were seeded as described above. After 48 hours, the glass 180 
support on which the cells were cultured were stained with 2′,7′-dichlorofluorescin diacetate (DCFDA) 181 
(Sigma-Aldrich) and MitoSOX™ Red Mitochondrial Superoxide Indicator (M36008, ThermoFisher) according 182 
to the manufacturer’s instructions. Cell were fixed as described above and analyzed by confocal 183 
microscopy. The acquired data were processed by the ImageJ processing program. Kelly cells were treated 184 
as described above, detached, stained with DCFDA, and subjected to flow cytometry with the CytoFLEX 185 
cytometer (Beckman Coulter) for ROS quantification. Data were analyzed using FlowJo software. 186 
 187 
Neuroblastoma luminescent cells. Phoenix-Ampho cells were transfected with Lipofectamine 2000 188 
(Invitrogen) and plasmid pMMP-Lucneo (kindly provided by Professor Andrew Kung, Harvard Medical 189 
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School, Boston, MA). The viral particles were collected at 48 and 72 hours post transfection. The Kelly cell 190 
line was spinoculated with the viral particles and polybrene (hexadimethrine bromide, Sigma). The cells 191 
were subjected to selection for 15 days with 1 mg/mL of G418 (Calbiochem). The best cell clones were 192 
selected and their luminescence was measured. The resulting cell line was named Kelly-luc. 193 
 194 
Xenograft ectopic neuroblastoma mouse model. All experiments were approved by the Scientific Ethical 195 
Committee of Bologna University (protocol n. 07/73/2013 and 564/2018-PR). Four to six week old 196 
NOD/SCID CB17 mice of both sex were inoculated with 10x106 Kelly-luc cells in Corning®Matrigel® Matrix. 197 
Mice were sedated with isoflurane prior to the injection. The pellet was inoculated by injection in the 198 
dorso-posterior-lateral position. The growth of the tumor was evaluated by luminescence acquisition. D-199 
Luciferine was administered by I.P. injection. Luminescence was acquired by the UviTec imaging system 200 
(Uvitec, Cambridge, UK). Treatment was performed after the tumor reached the pre-defined starting point 201 
in the bioluminescent acquisition. PNA oligo was then administered to the treatment group every day for 202 
14 days. The animals were sacrificed at day fifteen. The tumors were removed, measured, weighed, and 203 
fixed in 4% formalin. For the event free survival curve, mice were treated daily with a dorsal subcutaneous 204 
injection of 100 L of vehicle or BGA002 (10 mg/kg/day) for 28 days. Animals were monitored once every 205 
other day for tumor diameter measurement (using a caliper) and total tumor volume was extrapolated. An 206 
endpoint of at least 10mm tumor diameter and a total tumor volume of 523mm3 was established. 207 
 208 
Immunohistochemistry. The neuroblastoma tumors were dehydrated, embedded in paraffin, and cut into 209 
4 μm sections. Paraffin removal was accomplished by incubating histological slides in toluene followed by 210 
incubation in ethanol. The slides were incubated in 2% H2O2-methanol for inhibition of endogenous 211 
peroxidase activity. Hydration was performed by serial incubation with 96% ethanol, 70% ethanol, and 212 
distilled water. Antigen retrieval was performed by heat processing in 1mM EDTA, pH 8, for N-Myc 213 
antibody and in 10mM Citrate pH 6 for TRAP1. The slides were blocked with 10% BSA in PBS, stained with 214 
the N-Myc (OP13, Calbiochem), Ki-67 (MIB1, Dako), and TRAP1 (TR1, Santa Cruz) antibodies and 215 
subsequently treated with secondary antibody (anti-mouse, Dako). The peroxidase coloration reaction was 216 
performed using the Dako DAB kit. The slides were stained with haematoxylin, dehydrated, and mounted. 217 
Images were acquired with the Leitz Diaplan microscope. 218 
 219 
Statistical analysis. Statistical analysis was performed with the Prism software version 6 (GraphPad) or with 220 
R software version 3.5. Python software version 3.0 was used to perform t-SNE. The different analyses and 221 
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 225 
BGA002 is a novel MYCN-specific antigene oligonucleotide with potently improved MYCN transcriptional 226 
inhibition 227 
 228 
We have previously reported on the effect of a MYCN-specific antigene PNA (agPNA) oligonucleotide 229 
(BGA001) for the selective inhibition of MYCN in NB cell lines. This inhibition led to decreased transcription, 230 
reduced cell viability, and apoptosis (16). Furthermore, the MYCN agPNA was able to inhibit MYCN 231 
transcription in rhabdomyosarcoma cell lines, which led to anti-tumor activity in vivo in mice (17). Thus, our 232 
first aim was to compare the effects of the novel MYCN-specific agPNA oligonucleotide (BGA002) with the 233 
previous one (BGA001). BGA002 was conjugated to a nuclear localization signal (NLS) peptide for delivery 234 
(16,21,22), because it was previously found to facilitate penetration of BGA001 into cells, without requiring 235 
a transfection agent, and localization to the nucleus. Indeed, BGA002 showed potently enhanced activity in 236 
down-regulating MYCN mRNA expression in comparison with the agPNA BGA001 in MNA-NB cells (Fig. 1A).  237 
Moreover, BGA002 was much more efficient in reducing cell viability and N-Myc protein degradation than 238 
BGA001 (Fig. 1B and 1C), and in inducing apoptosis at 24 and 48 hours (Fig. 1D and S1A).  Therefore, as 239 
demonstrated by the EC50 comparison, BGA002 shows a stronger anti-tumor effect in vitro in comparison 240 
with the previous agPNA (Supplementary Table 3).    241 
To evaluate the in vitro activity of BGA002 in NB, we selected a panel of twenty cell lines to cover the broad 242 
landscape of NB tumors: MNA cell lines (n = 10), MNA/p53mut (n = 4), not-MNA (n = 5), and not-MNA/p53mut 243 
(n = 1). All the selected NB cell lines, showed expression of MYCN mRNA, with consistently higher levels 244 
detected in MNA cell lines (Fig. S2A). BGA002 shows a strong dose-dependent inhibitory effect on MYCN 245 
transcription and on cell viability (Fig. 1E and F, S2B and D). MNA cell lines were significantly more 246 
susceptible to the effects of BGA002 as demonstrated by a lower EC50 compared to the MNA/p53mut cell line 247 
(Fig. 1F).  248 
As expected, BGA002 was MYCN-specific, and did not influence cell viability in the MYCN-unexpressed 249 
HEK293 cells (Fig. S3A), while a mutated version of BGA002 (BGA002mut) did not have any effect on MYCN 250 
transcription (Fig. S3B), on cell viability of MYCN-expressing MNA-NB cells (Fig. S3C), on N-Myc downstream 251 
targets (Fig. S3D), and on inducing apoptosis (Fig. S3E-F). Moreover, BGA002 bound to the unique target 252 
DNA sequence in the MYCN gene, while BGA002mut showed no binding (Fig. S3G). 253 
 254 
Specific MYCN-inhibition by BGA002 leads to profound mitochondrial damage in MNA-NB cells 255 
 256 
Since MYCN mRNA inhibition persisted at 48 hours (Fig. S2C), at which time we found extensive apoptosis 257 
levels (Fig. 1D), we decided to perform transmission electron microscopy to investigate the leading cause of 258 
this phenomenon. Ultrastructural analysis showed that MYCN inhibition by BGA002 caused profound 259 
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mitochondrial changes in MNA-NB cells. After 12 hours, we observed initial mitochondrial damage (Fig. 260 
S4A) without concomitant apoptosis (Fig. S4B and C), suggesting that apoptosis is a consequence of the 261 
observed phenomenon, rather than the cause. After 48 hours (or 72 hours) of BGA002 treatment, the 262 
mitochondria had sustained extensive damage (Fig. 2A, Fig. S5C) while at 24 hours we noticed that 263 
mitochondria became smaller and the cristae patterns were much less elaborate (Fig. S5B). Indeed, 264 
mitochondrial alterations were not observed after treatment with a mutated control antigene PNA 265 
(BGA002mut), after 48 hours or at 72 hours (Fig.  S5A and C). 266 
Generally the distribution and connection pattern is indicative of mitochondrial mass and function (23,24). 267 
While Mito-Tracker staining reveals that in the untreated MNA-NB cells the mitochondria are highly 268 
interconnected, anti-MYCN BGA002 treatment disrupted these mitochondrial nets, and the mitochondrial 269 
content appears to be reduced (Fig. 2B and S5D). Moreover, BGA002 induced a change in the mitochondrial 270 
pattern, resulting in a perinuclear distribution (Fig. 2B). As before, BGA002mut failed to affect the 271 
mitochondrial nets (Fig. S5D). Interestingly, we observed much less mitochondrial damage and pattern 272 
alteration after 48 hours of BGA001 (Fig. S6A-B). Furthermore, BGA002 treatment led to a decrease in 273 
mitochondrial area per cell (25) in the MNA cells (Fig. S7A), and we observed a BGA002 dose-dependent 274 
mitochondrial mass reduction after 48 and 72 hours of treatment (Fig. S7B-C). 275 
 276 
Alterations in mitochondrial pathways can identify neuroblastoma patients with poor survival prognosis  277 
 278 
To verify the impact of mitochondrial gene signature on neuroblastoma prognosis we selected genes from 279 
the GO mitochondrial pathways and from the available literature (1718 genes, Supplementary Table 4). For 280 
this purpose we used a publicly available dataset that included patient clinical annotations (26). We used 281 
the mitochondrial related signature to conduct a self-organization map to separate gene expression profiles 282 
from NB in two different clusters of patients (Fig. 3A-C, S8A, Supplementary Table 5). The two clusters have 283 
a statistically significant difference in the overall survival rates and event-free probability (Fig. 3D, S8B), 284 
with cluster 2 strongly linked with a poor survival prognosis. Indeed, cluster 2 shows a similar worsening of 285 
the overall survival probability for the MNA patient subgroup (Fig. 3E). We further investigated which genes 286 
had a larger effect on event-free and overall survival. For this purpose, we used a random forest model 287 
optimized for censored data to conduct feature selection. The variables extracted from the model and from 288 
the self-organization map were used to construct a MitoScore. The top 200 genes qualifying for MitoScore 289 
are shown in word cloud (Fig. 3F, S8C, Supplementary Table 6). The genes present in MitoScore and 290 
differentially expressed in the two clusters (Supplementary Table 7) were used to identify which functional 291 
pathways were linked to each cluster. Filtering the insignificant pathways, we found 20 GO pathways 292 
specific for cluster 1 and 45 for cluster 2 (Fig. 3G, Supplementary Table 8 and 9). As expected, analysis 293 
highlighted the presence of a substantial number of folic acid pathway genes in cluster 2, since it is known 294 
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that MYCN amplified neuroblastomas have an enhanced dependency on folate (27). Moreover, cluster 2 295 
contains a number of genes in response to ROS genes (RROS) (Fig. 3G, Supplementary Table 9). Conversely, 296 
we found that cluster 1 contained a significant number of genes related to mitophagy (Fig. 3G, 297 
Supplementary Table 9). Based on pathway analysis we built an RROS score and a mitophagy score. The 298 
high presence of genes related to response to ROS was significantly predictive for overall survival. It was 299 
also noted that that a lower number of genes present related to mitophagy significantly worsened the 300 
overall survival probability (Fig. 3H). The RROS and mitophagy scores showed significant inverse correlation 301 
(Pearson coefficient = -0.73, pvalue = 2.2e-16). Interestingly, the presence of MYCN correlated well with the 302 
RROS score (0.63, pvalue = 2.2e-15) and showed inverse correlation with the mitophagy score (-0.73, 303 
pvalue = 2.2e-16) (Fig. S8E). Ultimately, it was noted that the results from MYCN-amplified patients showed 304 
a substantial presence of mitochondrial related signature genes and a higher RROS score in comparison 305 
with patients lacking MYCN-amplification (Fig S9A) 306 
 307 
BGA002 reverts N-Myc dysregulated mitochondrial pathways in MNA-NB 308 
 309 
MYCN alteration of the transcriptional program is critical in promoting tumorigenesis in MNA-NB. Given 310 
this view, we investigated the effects of MYCN inhibition by BGA002 on gene expression profiles in several 311 
NB cell lines. As expected, genes present in the mitochondrial signature, and with a high score, show 312 
different expression levels between cluster 1 and cluster 2 (Fig. 4A). Surprisingly, we found the same 313 
behavior in MYCN-amplified versus MYCN non-amplified patients (Fig. 4A). Furthermore, we noticed that 314 
these genes are significantly predictive for overall survival (Fig. 4B). We also found that different genes in 315 
the mitochondrial signature correlate well or show inverse correlation with MYCN in the dataset of patient 316 
gene expression profiles (Fig. 4C). Based on these results, we investigated if MYCN inhibition by BGA002 317 
was able to down-regulate genes from the mitochondrial signature (Fig. 4D). MYCN inhibition led to the 318 
down-regulation of a wide group of mitochondrial genes in the different NB cell lines. MYCN silencing by 319 
BGA002 also down-regulated other previously described MYCN-related genes (Fig. 4D), including TERT and 320 
SKP2 (28,29). The use of an anti-MYCN siRNA and the Tet21N cells (in which inducible MYCN silencing is 321 
achieved by tetracycline administration, but not by BGA002, since these cells lack the agPNA target 322 
sequence in the inserted MYCN construct (Fig. S10A)(30) as controls, resulted in the same gene expression 323 
pattern (Fig. 4D). Interestingly, by confirming MYCN correlation with a response to ROS and an inverse 324 
correlation with mitophagy as previously shown, we found that MYCN-inhibition down-regulated the gene 325 
expression of TRAP1 while up-regulating the expression of OPTN (Fig. 4D). These genes are involved in 326 
mitochondrial ROS control and in mitophagy, respectively (31–33). We also confirmed mitochondrial 327 
protein production variation in MNA-NB cells, a concomitant decrease in TRAP1, and an increase in OPTN 328 
production (Fig. 4E). Moreover, TRAP1 decrease and OPTN increase are accentuated at 48 hours (Fig. 4E). 329 
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Based on our finding that MYCN shows inverse correlation with the mitophagy score in NB and on the well 330 
described important positive role of OPTN in this pathway (32), we investigated the inhibitory role of MYCN 331 
on mitophagy activation. In Tet21N cells after MYCN-silencing (72 hours of tetracycline administration) 332 
while not observing apoptosis, (Fig. S10B and C), we registered a dramatic decrease in mitochondrial 333 
number (Fig. S10D). Concomitantly, we observed the appearance of a high number of myelin figures (Fig. 334 
4F) and co-localization of mitochondria with lysosomes (Fig.S10E). Collectively, these findings are indicative 335 
of mitophagy activity after MYCN inhibition. Finally, an siRNA anti-OPTN significantly reduced mitophagy 336 
activity after MYCN silencing in Tet21N cells (Fig. S11A-D) 337 
 338 
 339 
BGA002 leads to loss of protective N-Myc effect against mitochondrial ROS through TRAP1 340 
downregulation in MNA-NB 341 
 342 
Based on our finding of a positive correlation between MYCN expression and the RROS score in the poor 343 
survival prognosis cluster 2 from the NB patient dataset (Fig. S8E), we investigated if MYCN inhibition by 344 
BGA002 could induce augmentation of mitochondrial ROS production. Indeed, BGA002 treatment induced 345 
up-regulation of the ROS and an increase in superoxide production (Fig. 5A, S12A). Since TRAP1 plays a 346 
determining role in mitochondrial ROS control and considering that BGA002 treatment down-regulated 347 
TRAP1 expression, we investigated if TRAP1 inhibition led to an increment in ROS production in MNA-NB. 348 
Indeed, siRNA against TRAP1 (siTRAP1) led to an increment in production of ROS in mitochondria (Fig. 5A). 349 
TRAP1 downregulation by siTRAP1 also inhibited the mitochondrial net structure (Fig. 5B), similar to MYCN 350 
inhibition after BGA002 treatment. Moreover, siTRAP1 consistently reduced cell viability (Fig. 5C). As a 351 
control, we verified that siTRAP1 did not affect MYCN mRNA expression (Fig. 5D).  Interestingly, in Tet21n 352 
cells, which showed mitophagy reactivation after MYCN silencing (by tetracycline administration) and did 353 
not undergo apoptosis, we did not find an appreciable increase in ROS production (Fig. S12B). Moreover, 354 
BGA002mut failed to induce ROS production, while BGA001 showed a modest effect (Fig. S12C) and the 355 
latter did not consistently reduce TRAP1 mRNA expression (Fig. S12D). This mechanism is graphically 356 
represented in Fig. S13A. 357 
 358 
BGA002 causes elimination of MNA-NB in mice 359 
 360 
Finally, we evaluated the in vivo anti-tumor activity of BGA002 in a xenograft murine model of MNA-NB. 361 
We inoculated MNA-NB Kelly-luminescent cells, which were monitored until tumor luminescence was 362 
detectable. Treatment with BGA002 resulted in a statistically significant augmentation of survival in 363 
comparison with the vehicle (Fig. 6A, S13B). 364 
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Moreover, subcutaneous administration (daily for 15 days) of BGA002 resulted in a potent and dose-365 
dependent anti-tumor activity. BGA002 at 2.5 mg/kg/day caused a tumor weight decrease of 25%, while 366 
the treatment with 5 mg/kg/day resulted in a significant decrease of more than 70%, and administration at 367 
10 mg/kg/day led to tumor elimination (Fig. 6B). We concluded that treatment with BGA002 showed a 368 
dose-response tumor growth inhibition. 369 
After treatment with BGA002 at the intermediate dose (5 mg/kg/day), histological analysis revealed a 370 
consistent reduction in tumor vascularization as compared to the vehicle group (Fig. 6C), while 371 
immunohistochemical analysis, showed a consistent reduction in N-Myc protein staining, a decrease in Ki-372 




  377 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 13 
Discussion  378 
 379 
The critical role of N-Myc in cancer development and its association with poor survival prognosis is not 380 
restricted to neuroblastoma, with a broad range of tumors available in which MYCN-amplification and over-381 
expression play a crucial role (34). Due to the highly restricted pattern of expression of MYCN in normal 382 
cells, N-Myc represents an optimal target for tumor-specific therapy for MYCN-expressing tumors.  383 
While the direct targeting of the N-Myc transcription factor protein is still challenging, antigene therapy by 384 
targeting MYCN transcription has great potential in treating MYCN-expressing tumors, as we previously 385 
demonstrated in the preclinical treatment of neuroblastoma and rhabdomyosarcoma by a MYCN-specific 386 
antigene PNA (16,17).  387 
Here we report for the first time, the preclinical results for BGA002, a novel MYCN-specific agPNA with 388 
potently improved ability to block MYCN transcription. The BGA002 sequence is complementary to a 389 
unique target sequence in the human (and mouse) MYCN gene. BGA002 showed dose-dependent inhibition 390 
of MYCN transcription and cell viability in a panel of twenty MYCN-expressing NB cell lines with or without 391 
MNA. In comparison to BGA001, it showed a potently enhanced ability to specifically decrease MYCN 392 
mRNA and protein expression while decreasing the viability of NB cell lines. 393 
Interestingly, BGA002 is more effective in NB cell lines with MNA versus p53-mutated or MYCN single copy 394 
cell lines. Since, MYCN inhibition led to apoptosis, the higher EC50 found in p53-mutated NB cells could be 395 
explained by their higher resistance to apoptosis (35).  MYCN inhibition led to the down- or up-regulation of 396 
highly relevant genes involved in metabolism, cell cycle control, apoptosis, metastasis, and DNA repair.  397 
Surprisingly, the main ultrastructural alteration that we found in MNA-NB cells after MYCN inhibition, was 398 
alteration of mitochondrial structure and organization. Interestingly, BGA001, which showed much less 399 
ability to induce mitochondrial alteration, exerted a lesser effect in the promotion of apoptosis.  We also 400 
showed that a gene expression signature related to mitochondria allows for the identification of 401 
neuroblastoma patients with poor survival prognosis. Furthermore, we found that BGA002 treatment led to 402 
the down- or up-regulation of different genes involved in this signature.  403 
It is known that metabolic stress generally leads to autophagy (36), but its role in cancer is still controversial 404 
(37,38).  The impact of autophagy in neuroblastoma is also controversial (39) and depends on the p53 405 
status of the cells (40). Moreover, mitophagy (a particular type of autophagy) is a fundamental process for 406 
mitochondrial turnover and health, and its deregulation can result in neurodegenerative disease and cancer 407 
insurgence (41,42). Interestingly, we found that low enrichment in mitophagy related genes is significantly 408 
predictive for a poor survival prognosis in a large dataset of gene expression profiles from NB patients. 409 
Furthermore, we noticed that MYCN inhibition led to the up-regulation of OPTN, which plays an important 410 
role in mitophagy induction (32,33). Moreover, blocking MYCN expression in Tet21N cells led to the 411 
disappearance of mitochondria with concomitant presence of myelin figures, and co-localization of 412 
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lysosomes with mitochondria, indicating mitophagy activation. This phenotype is significantly reduced after 413 
siRNA anti-OPTN administration, indicating that N-Myc blocks mitophagy through OPTN silencing.  414 
ROS generation in mitochondria plays a role in cancer initiation, with many mitochondrial processes leading 415 
to ROS generation in tumor cells (43). Notwithstanding their role in tumorigenesis, ROS excess in cells leads 416 
to damage and ultimately to apoptosis (44). TRAP1 is a mitochondrial chaperone protein that plays a crucial 417 
role in mitochondrial homeostasis (31), and its down-regulation corresponds to an increase in ROS 418 
presence, and to a higher susceptibility to oxidative stress (31). We found that inhibition of MYCN led to 419 
TRAP1 down-regulation, an increase ROS generation, and induction of apoptosis in MNA-NB cells. 420 
Furthermore, BGA001 modestly reduced TRAP1 expression and showed a less effective ability to induce 421 
ROS and promote apoptosis, indicating that N-Myc mitochondrial protection plays a relevant role in 422 
neuroblastoma. 423 
There is a growing corpus of evidence that mitochondrial fate is connected to tumor formation and 424 
progression (45,46). Neuroblastoma insurgence leads to profound metabolic changes, where high risk 425 
neuroblastoma shows a higher uptake of glucose and a reduction in oxidative phosphorylation in 426 
mitochondria (47). Although it has been claimed that N-Myc was involved in mitochondrial lipid metabolism 427 
in NB (11), its role in mitochondrial regulation in NB was largely unknown. 428 
Here, we describe for the first time that N-Myc is relevant in mitochondrial structural maintenance and 429 
turnover. Our work highlights the prognostic value of mitochondrial dysregulation in NB patients and 430 
provides a mechanism on how N-Myc controls previously unknown aspects of mitochondrial function, by 431 
inhibiting mitophagy, and controlling ROS generation.  432 
Considering the role of N-Myc in a wide range of tumors, further studies on its close relationship with 433 
mitochondria will provide other valuable insights in cancer biology. Furthermore, considering the role of 434 
MYCN in mitochondrial ROS protection, it will be interesting to analyze the potential use of BGA002 in 435 
conjunction with other therapies that induce ROS in cancer cells.  436 
BGA002 has received orphan drug designation from the Food and Drug Administration (orphan registry: 437 
DRU-2017-6085) and from the European Medicines Agency (orphan registry: EU/3/12/1016). Based upon 438 
its well tolerated regulatory safety profile package, BGA002 is now moving to phase I clinical trials in 439 
Neuroblastoma patients. 440 
 441 
Acknowledgments 442 
We would like to thank Wissem Eljeder and Simone Maestri for suggestions and comments. We would like 443 
also to thank Andres E. Zucchetti from the Institut Curie for insightful suggestions on confocal microscopy 444 
analysis. 445 
 446 
  447 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 15 
References  448 
 449 
1.  Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. 450 
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 451 
2015;33:3008–17.  452 
2.  Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, et al. 453 
Association of MYCN copy number with clinical features, tumor biology, and outcomes in 454 
neuroblastoma: A report from the Children’s Oncology Group. Cancer. 2017;123:4224–35.  455 
3.  Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of 456 
MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16:2985–95.  457 
4.  Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in 458 
untreated human neuroblastomas correlates with advanced disease stage. Science. 459 
1984;224:1121–4.  460 
5.  Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of 461 
multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J 462 
Med. 1985;313:1111–6.  463 
6.  Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013;3.  464 
7.  Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. 465 
Neuroblastoma. Nat Rev Dis Primer. 2016;2:16078.  466 
8.  Dang CV, Kim J, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev 467 
Cancer. 2008;8:51–6.  468 
9.  Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, et al. ATF4 Regulates MYC-mediated 469 
Neuroblastoma Cell Death upon Glutamine Deprivation. Cancer Cell. 2012;22:631–44.  470 
10.  Ruiz-Pérez MV, Henley AB, Arsenian-Henriksson M. The MYCN Protein in Health and 471 
Disease. Genes. 2017;8.  472 
11.  Zirath H, Frenzel A, Oliynyk G, Segerström L, Westermark UK, Larsson K, et al. MYC 473 
inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. 474 
Proc Natl Acad Sci U S A. 2013;110:10258–63.  475 
12.  Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, et al. 476 
Differential expression of myc family genes during murine development. Nature. 477 
1986;319:780–3.  478 
13.  Fletcher JI, Ziegler DS, Trahair TN, Marshall GM, Haber M, Norris MD. Too many targets, 479 
not enough patients: rethinking neuroblastoma clinical trials. Nat Rev Cancer. 2018;18:389–480 
400.  481 
14.  Janowski BA, Kaihatsu K, Huffman KE, Schwartz JC, Ram R, Hardy D, et al. Inhibiting 482 
transcription of chromosomal DNA with antigene peptide nucleic acids. Nat Chem Biol. 483 
2005;1:210–5.  484 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 16 
15.  Janowski BA, Huffman KE, Schwartz JC, Ram R, Hardy D, Shames DS, et al. Inhibiting gene 485 
expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem 486 
Biol. 2005;1:216–22.  487 
16.  Tonelli R, Purgato S, Camerin C, Fronza R, Bologna F, Alboresi S, et al. Anti-gene peptide 488 
nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to 489 
cell growth inhibition and apoptosis. Mol Cancer Ther. 2005;4:779–86.  490 
17.  Tonelli R, McIntyre A, Camerin C, Walters ZS, Leo KD, Selfe J, et al. Antitumor Activity of 491 
Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene 492 
Therapy. Clin Cancer Res. 2012;18:796–807.  493 
18.  Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by 494 
strand displacement with a thymine-substituted polyamide. Science. 1991;254:1497–500.  495 
19.  Clayton DA, Shadel GS. Isolation of Mitochondria from Tissue Culture Cells. Cold Spring 496 
Harb Protoc. 2014;2014:pdb.prot080002.  497 
20.  Dolman NJ, Chambers KM, Mandavilli B, Batchelor RH, Janes MS. Tools and techniques to 498 
measure mitophagy using fluorescence microscopy. Autophagy. 2013;9:1653–62.  499 
21.  Boffa LC, Cutrona G, Cilli M, Matis S, Damonte G, Mariani MR, et al. Inhibition of Burkitt’s 500 
lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the 501 
translocated c-myc. Cancer Gene Ther. 2007;14:220–6.  502 
22.  Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, Ferrarini M, et al. Effects in live 503 
cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol. 504 
2000;18:300–3.  505 
23.  Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol 506 
Cell Biol. 2007;8:870–9.  507 
24.  Sauvanet C, Duvezin-Caubet S, di Rago J-P, Rojo M. Energetic requirements and bioenergetic 508 
modulation of mitochondrial morphology and dynamics. Semin Cell Dev Biol. 2010;21:558–509 
65.  510 
25.  Vowinckel J, Hartl J, Butler R, Ralser M. MitoLoc: A method for the simultaneous 511 
quantification of mitochondrial network morphology and membrane potential in single cells. 512 
Mitochondrion. 2015;24:77–86.  513 
26.  Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, et al. Revised Risk 514 
Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma 515 
Patients by Integrating Clinical and Molecular Prognostic Markers. Clin Cancer Res. 516 
2015;21:1904–15.  517 
27.  Lau DT, Flemming CL, Gherardi S, Perini G, Oberthuer A, Fischer M, et al. MYCN 518 
amplification confers enhanced folate dependence and methotrexate sensitivity in 519 
neuroblastoma. Oncotarget. 2015;6:15510–23.  520 
28.  Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, et al. SKP2 is a direct 521 
transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Cancer 522 
Lett. 2015;363:37–45.  523 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 17 
29.  Nikiforov MA, Chandriani S, Park J, Kotenko I, Matheos D, Johnsson A, et al. TRRAP-524 
Dependent and TRRAP-Independent Transcriptional Activation by Myc Family Oncoproteins. 525 
Mol Cell Biol. 2002;22:5054–63.  526 
30.  Wasylishen AR, Stojanova A, Oliveri S, Rust AC, Schimmer AD, Penn LZ. New model 527 
systems provide insights into Myc-induced transformation. Oncogene. 2011;30:3727–34.  528 
31.  Masgras I, Sanchez-Martin C, Colombo G, Rasola A. The Chaperone TRAP1 As a Modulator 529 
of the Mitochondrial Adaptations in Cancer Cells. Front Oncol. 2017;7.  530 
32.  Moore AS, Holzbaur ELF. Dynamic recruitment and activation of ALS-associated TBK1 with 531 
its target optineurin are required for efficient mitophagy. Proc Natl Acad Sci U S A. 532 
2016;113:E3349–58.  533 
33.  Richter B, Sliter DA, Herhaus L, Stolz A, Wang C, Beli P, et al. Phosphorylation of OPTN by 534 
TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged 535 
mitochondria. Proc Natl Acad Sci U S A. 2016;113:4039–44.  536 
34.  Rickman DS, Schulte JH, Eilers M. The Expanding World of N-MYC–Driven Tumors. Cancer 537 
Discov. 2018;8:150–63.  538 
35.  Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, et al. Chemotherapy-539 
Induced Apoptosis in a Transgenic Model of Neuroblastoma Proceeds Through p53 Induction. 540 
Neoplasia N Y N. 2008;10:1268–74.  541 
36.  Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev 542 
Mol Cell Biol. 2018;19:349–64.  543 
37.  Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and 544 
cancer. Nat Cell Biol. 2018;20:243–51.  545 
38.  Wilde L, Tanson K, Curry J, Martinez-Outschoorn U. Autophagy in cancer: a complex 546 
relationship. Biochem J. 2018;475:1939–54.  547 
39.  Frentzel J, Sorrentino D, Giuriato S. Targeting Autophagy in ALK-Associated Cancers. 548 
Cancers. 2017;9.  549 
40.  Mrakovcic M, Fröhlich LF. p53-Mediated Molecular Control of Autophagy in Tumor Cells. 550 
Biomolecules. 2018;8.  551 
41.  Bordi M, Nazio F, Campello S. The Close Interconnection between Mitochondrial Dynamics 552 
and Mitophagy in Cancer. Front Oncol. 2017;7.  553 
42.  Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, 554 
physiology and pathology. Nat Cell Biol. 2018;20:1013–22.  555 
43.  Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an 556 
Achilles’ heel? Nat Rev Cancer. 2014;14:709–21.  557 
44.  Murphy MP, Holmgren A, Larsson N-G, Halliwell B, Chang CJ, Kalyanaraman B, et al. 558 
Unravelling the Biological Roles of Reactive Oxygen Species. Cell Metab. 2011;13:361–6.  559 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 18 
45.  Sciacovelli M, Gonçalves E, Isaac Johnson T, Roberto Zecchini V, da Costa ASH, Gaude E, et 560 
al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 561 
2016;537:544–7.  562 
46.  Vyas S, Zaganjor E, Haigis MC. Mitochondria and Cancer. Cell. 2016;166:555–66.  563 
47.  Aminzadeh S, Vidali S, Sperl W, Kofler B, Feichtinger RG. Energy metabolism in 564 
neuroblastoma and Wilms tumor. Transl Pediatr. 2015;4:20–32.  565 
 566 
  567 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 19 
Figure legends 568 
 569 
Figure 1. 570 
BGA002 is a new specific anti-MYCN antigene oligonucleotide with potently improved MYCN 571 
transcription inhibition properties leading to cell-growth inhibition and apoptosis in Neuroblastoma cells.  572 
A – E, Comparison of the in vitro efficacy between neuroblastoma cells (Kelly and SK-N-BE(2)c) treated with 573 
different doses of BGA001 and BGA002. Bars represent the mean, whiskers indicate standard deviation. A, 574 
MYCN mRNA expression inhibition through RT-PCR after 12 hours of treatment, BGA001 (gray) and BGA002 575 
(red) (n = 3, biological replicates for each cell line). B, Cell viability assay showing a decrease after 72 hours 576 
of treatment, BGA001 (gray) and BGA002 (red) (n = 3, biological replicates for each cell-line). C, 577 
Representative western blot analysis of N-Myc after 24 hours. Representative staining for N-Myc (above) 578 
and whole-lane coomassie staining are presented (bottom). Quantification of N-Myc expression 579 
(normalized with coomassie staining) is presented in the top panel. Bars represent the mean, whiskers 580 
indicate standard deviation (n = 2, biological replicates for each cell line). BGA001 is shown on the left, and 581 
BGA002 on the right, Kelly cell line is shown in the first line, SK-N-BE(2)c is shown in the second line. D, the 582 
bar represents percentage of cells stained by Annexin V+ / PI+ for the cell line treated for 24 (left) or 48 583 
hours (right) (n = 3, biological replicates for each cell-line). E, Heatmap representing different 584 
neuroblastoma cell lines treated with different doses of BGA002. MYCN mRNA expression inhibition 585 
through RT-PCR (left) after 12 hours of treatment and a decrease in cell viability after 72 hours of treatment 586 
(right). The red scale represents the average percentage of inhibition of different biological replicates for 587 
each cell line (n = 3) normalized to the control. F, mRNA MYCN inhibition (left) and vitality decrement 588 
(right) EC50 for each cell line grouped according to MYCN amplification and/or p53 mutation. Each dot 589 
represents a singular experiment (n = 3 for each cell-line). Each point represents an individual sample, 590 
middle line indicates the median, box limits indicate the first and third quartiles, the whiskers indicate 591 
samples within 1.5 times the interquartile range (test = Wilcoxon matched pair test. pValue: *, p < 0.05, **, 592 
p < 0.01, ***, p < 0.001). 593 
 594 
Figure 2. 595 
BGA002 leads to MYCN-specific structural and functional alterations in mitochondria in MNA-NB cells.  596 
A, Transmission electron micrographs of the Kelly cell line treated for 48 hours with 5 µM BGA002. 597 
Untreated cells are shown in the first row, BGA002 treated cells are shown in the second row. 598 
Abbreviations used: M: mitochondrion, N: nucleus.   B, Evaluation of mitochondrial nets in the Kelly cell line 599 
treated for 48 hours with 5 µM BGA002.  600 
 601 
Figure 3. 602 
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Alterations in mitochondrial pathways identify neuroblastoma patients with poor survival prognosis. 603 
 A, Schematic representation of the bioinformatic pipeline analysis conducted. A dataset of neuroblastoma 604 
gene expression profiles (GEP) has been downloaded. Genes selected from the literature or listed in GO as 605 
part of  the mitochondrial associated terms were used to generate a mitochondrial related signature. A 606 
self-organization map (SOM) was utilized to associate patient GEPs to two different clusters with a different 607 
survival probability. The genes in the mitochondrial related signature were ranked by their contribution to 608 
the separation of patient GEPs in two different clusters. Their contributions to predicting overall survival 609 
and event-free survival were also taken into account to build a MitoScore for all the genes present in the 610 
mitochondrial related signature. We used genes in the MitoScore that were differentially expressed to build 611 
a functional grouped network of pathways. B, Heatmap showing the two different clusters (cluster1 in 612 
green, cluster2 in red) derived from the self-organization map. Each square represents a neuron; the size of 613 
the inner square is proportional to the number of patient GEPs associated with that neuron. C, T-614 
distributed stochastic neighbor embedding showing the clustering of the transcriptional profiles 615 
(considering the genes present in the mitochondrial related signature) of the patient GEPs. Each dot 616 
represents a patient transcriptional profile, the dots are colored according to which cluster they belong to 617 
(cluster1 (n = 541) in green, cluster2 (n= 122) in red). D, Kaplan–Meier plots for the probability of overall 618 
survival over time for patients associated with cluster 1 (green, n = 541) and cluster 2 (red, n = 161). 619 
Associated P value (log-rank test) is shown in the middle. Hazard ratio and associated P value (log-rank test) 620 
are shown in the bottom left of the plot. E, Kaplan–Meier plots for the probability of overall survival over 621 
time for patients associated with cluster 1 (green) and cluster 2 (red), MNA patient (light red, n = 122) and 622 
non-MNA patient (light green, n = 580). F, Word cloud of the top 200 genes ranked by MitoScore, the size is 623 
proportional to the associated MitoScore. G, Functional grouped network of the pathways up-regulated in 624 
cluster 1 (in green) and cluster 2 (in red). Circle size is proportional to the P value (FDR < 0.05). H, Kaplan–625 
Meier plots for the probability of overall survival over time for patients associated with Response to ROS 626 
score (low enriched, n = 614, high enriched, n = 88, top panel) and Mitophagy score (low enriched, n = 73, 627 
high enriched, n = 629, bottom panel). P value associated with the curve is shown in the middle of the plot 628 
(log-rank test). Hazard ratio and associated P value (log-rank test) are shown in the bottom left of the plot. 629 
(*, p < 0.05, **, p < 0.01, ***, p < 0.001) 630 
 631 
Figure 4.  632 
Blocking of MYCN leads to MYCN-specific gene expression signature inhibition in NB cells and to 633 
mitophagy reactivation.  634 
A, Expression of different genes presented in the mitochondrial related signature in cluster 2, cluster 1, 635 
MNA and non-MNA patient gene expression profiles and presented as z-scores. Each point represents an 636 
individual sample, middle line indicates the median, the whiskers indicate samples within 1.5 times the 637 
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interquartile range (statistical test = Wilcoxon). B, Kaplan–Meier plots for the probability of overall survival 638 
over time for patients associated with different genes present in the mitochondrial related signature. For 639 
NME4, TRAP1, MRPL11, PPRC1, MRPS2 the dark gray line represents a z-score > 1, for OPTN a z-score < -1. 640 
Hazard ratio, p value (log-rank test) are shown in the bottom left of the plot. C-D, the gene names in the 641 
middle refer to both panels. C, the color scale represents Pearson’s correlation coefficient of genes present 642 
in the mitochondrial related signature (top) and other N-Myc targets (bottom) with MYCN in the patient 643 
GEP dataset. D, Heatmap of the gene expression variation in neuroblastoma cell lines (MNA, MNA/p53-644 
mut, non-MNA, non-MNA/ p53-mut) after 12 hours of BGA002 treatment (5 µM). On the right side of the 645 
heatmap, Kelly cells treated with anti-MYCN siRNA, and Tet21N cells treated with tetracycline (72 hours) 646 
are shown. The color scale represents the log2 fold change in comparison to the untreated cell line (n = 2 647 
for each cell line), gray (gene not expressed). Upper part: genes present in the mitochondrial related 648 
signature, bottom part: other N-Myc targets. E, Western blot analysis for TRAP1 (left, top row) and OPTN 649 
(right, top row), cytochrome C (middle row), and coomassie staining (bottom row) of Kelly untreated cells 650 
and BGA002 (5 µM) treated cells for 24 (first line) and 48 hours (second line). F, Transmission electron 651 
micrographs of Tet21N cultured cells treated without (first line) and with (second line) tetracycline and 652 
chloroquine for 72 hours. From left to right, increasing magnification.  Abbreviations used: M: 653 
mitochondrion, MF: myelin figure, L: lysosome, N: nucleus. (*, p < 0.05, **, p < 0.01, ***, p < 0.001). 654 
 655 
Figure 5. 656 
BGA002 reverts the MYCN control of ROS generation by TRAP1 down-regulation in MNA-NB cells. 657 
A, Representative confocal microscopy analysis of ROS production in Kelly untreated cells (first line), Kelly 658 
cells treated with 5 µM BGA002 (second line) for 48 hours, Kelly cells treated with anti-TRAP1 siRNA (third 659 
line) for 24 hours. Mitosox staining in red (left), DCFDA staining in green (middle), and merge (right). From 660 
left to right, increasing magnification.  B, Evaluation of mitochondrial nets in the Kelly cell line treated for 661 
48 hours with vehicle (first line), with 5 µM BGA002 (second line), and 50 nM anti-TRAP1 siRNA. From left 662 
to right, increasing magnification.  C, Kelly cell line treated with 50 nM siRNA anti-TRAP1. TRAP1 percentage 663 
of mRNA inhibition after 24 hours in the left panel, percentage of cell viability inhibition in the right panel 664 
(n = 2) after 72 hours. D, Kelly cell line treated with 50 nM siRNA anti-TRAP1, TRAP1, and MYCN showing 665 
percentage of mRNA inhibition after 24 hours (n= 3). 666 
 667 
Figure 6. 668 
BGA002 causes elimination of MNA-NB in mice through TRAP1 down-regulation.  669 
A, Kaplan–Meier plots for the probability of event-free survival over time for mice (Kelly-luc xenograft) 670 
treated with vehicle (red, n = 6) and BGA002, 10 mg/kg/day (green, n = 8). Associated P value (log-rank test) 671 
is shown in the middle. Hazard ratio and associated P value (log-rank test) are shown in the bottom left of 672 
Research. 
on October 22, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 15, 2019; DOI: 10.1158/0008-5472.CAN-19-0008 
 22 
the plot. B, Evaluation of tumor weight in neuroblastoma xenograft mice treated with different doses of 673 
BGA002 (untreated (n=21), 2.5 (n= 11), 5 (n=8), 10 (n=9) mg/kg/day). Each dot represents a mouse (test = 674 
Mann Whitney test). The table below the graph indicates the mean value of tumor weight reduction for 675 
each treatment dose in comparison to the control. C, Immunohistochemical analysis of neuroblastoma 676 
xenograft mice untreated (first line) or treated with 5 mg/kg/day BGA002(second line). Images of sections 677 
are shown stained with haematoxylin and eosin (first), Ki-67 antibody (second), N-Myc antibody (third), and 678 
Trap1 antibody (last). Similar results were obtained from four independent mice. (*, p < 0.05, **, p < 0.01, 679 
***, p < 0.001) 680 
 681 
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